Investors looking to earn income and keep pace with inflation should turn to dividend-growth stocks, according to investor Kevin Simpson.
This biotech made it through a ‘time correction.’ The charts say it could be time to buy
David Keller breaks down the charts on Incyte Corp.
Intel earnings are out Thursday. What Wall Street is expecting to see
The barrage of investments into Intel have quickly hiked its market cap, but largely failed to lift analysts’ conviction on the stock longer term.
IBM is trying to rebound after results disappointed initially. What analysts and investors are saying
Analysts remain largely divided on the future of the tech stalwart.
The Beyond Meat fever highlights the risk of trying to ride the meme trade wave
The violent swings underscored how quickly euphoria can turn to panic in these momentum-fueled trades.
This brokerage stock is 50% cheaper than Robinhood. Josh Brown sees an opportunity to buy the dip
Josh and Sean trade an under-the-radar brokerage stock that’s in all the same markets as Robinhood.
Meme stock trading is dominating the options market. Mike Khouw says beware the adrenaline rush
The danger is that meme stocks tend to spike rapidly and collapse just as fast.
These stocks reporting earnings next week usually beat the Street’s estimates and rally afterward
Some stocks issuing results next week have beaten estimates 75% of the time or more and rallied at least 2% the next day, Bespoke Investment Group data shows.
Here are Thursday’s biggest analyst calls: Tesla, Microsoft, IBM, Netflix, Booking Holdings & more
Here are Thursday’s biggest calls on Wall Street.
Core Scientific gets upgrade from Roth as CoreWeave deal becomes less likely
Roth Capital Partners believes that shares of Core Scientific could rally 27% from here.